zidesamtinib

all catalysts(0)

nothing on the calendar yet

News(4)

• FDA panel confronting peptide controversy
  Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
  stat · 19d ago
• GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
  Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…
  biospace · 19d ago
• GSK lung cancer drug gets speedy approval following $10.6B deal
  The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
  biopharma_dive · 20d ago
• GSK boosts cancer pipeline with $11B Nuvalent buyout
  The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.
  biopharma_dive · 2mo ago